ISSN: 1462-8902

Journal Home

Journal Guideline

Diabetes, Obesity and Metabolism Q1 Unclaimed

Wiley-Blackwell Publishing Ltd United Kingdom

Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

Diabetes, Obesity and Metabolism is a journal indexed in SJR in Endocrinology and Endocrinology, Diabetes and Metabolism with an H index of 153. It has a price of 3857 €. It has an SJR impact factor of 2,079 and it has a best quartile of Q1. It is published in English. It has an SJR impact factor of 2,079.

Diabetes, Obesity and Metabolism focuses its scope in these topics and keywords: diabetes, type, insulin, review, management, glargine, adjustment, inhibitors, randomized, systematic, ...

Type: Journal

Type of Copyright:

Languages: English

Open Access Policy: Open Choice

Type of publications:

Publication frecuency: -

Categories: Endocrinology (Q1) Endocrinology, Diabetes and Metabolism (Q1) Endocrinology, Diabetes and Metabolism (Q1) Internal Medicine (Q1)

Price

3857 €

Inmediate OA

NPD

Embargoed OA

0 €

Non OA

Metrics

2,079

SJR Impact factor

153

H Index

415

Total Docs (Last Year)

912

Total Docs (3 years)

16065

Total Refs

4956

Total Cites (3 years)

812

Citable Docs (3 years)

5.23

Cites/Doc (2 years)

38.71

Ref/Doc

Comments

No comments ... Be the first to comment!

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID *

* The email or ORCID field is only to validate the authenticity of the comment, the identity will not be public. .

Other journals with similar parameters

Endocrine Reviews Q1
Nature Reviews Endocrinology Q1
Nature Metabolism Q1
Diabetes Care Q1
Bone Research Q1

Compare this journals

Aims and Scope

Best articles by citations

Testosterone and leptin in a group of Chinese with and without diabetes

Differences in treatment and metabolic abnormalities between normo- and hypertensive patients with type 2 diabetes: the Skaraborg Hypertension and Diabetes Project

Editorial

Insulin-sensitizing action of rosiglitazone is enhanced by preventing hyperphagia

Isolation of human islets and beta-cells for pharmacological studies

Early insulin release effectively improves glucose tolerance: studies in two rodent models of type 2 diabetes mellitus

Influence of a combination of herbs on appetite suppression and weight loss in rats

What should the role of ACE inhibitors be in the treatment of diabetes? Lessons from HOPE and MICRO-HOPE

Lack of postprandial leptin peaks in patients with type 2 diabetes mellitus

FDA reviews troglitazone

N-phenacylthiazolium bromide decreases renal and increases urinary advanced glycation end products excretion without ameliorating diabetic nephropathy in C57BL/6 mice

Is insulin resistance the principal cause of type 2 diabetes?

SHOW MORE ARTICLES

News and views

Acute physiological effects of glucocorticoids on fuel metabolism in humans are permissive but not direct

A new hope in the nightmare of diabetic orthostatic hypotension: the midodrine-fludrocortisone association

Sudden death in type 1 diabetes

In-vivo and in-vitro models of type 2 diabetes in pharmaceutical drug discovery

Antilipolytic drugs for the prevention of primary ventricular fibrillation

Effects of antihyperglycaemic therapies on proinsulin and relation between proinsulin and cardiovascular risk factors in type 2 diabetes

Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus

Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, double-blind, placebo-controlled study

Impaired glucose metabolism and obesity in Swedish patients with borderline isolated systolic hypertension: Skaraborg Hypertension and Diabetes Project

Do baseline serum leptin levels predict weight regain after dieting in obese women?